title: Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
abstract: We have previously demonstrated that the cytokine interleukin 1 alpha (IL-1 alpha) significantly potentiates the antitumor activity of a variety of chemotherapeutic agents, including cisplatin (cDDP). In studies described here, we examined the potential of combining IL-1 alpha and the platinum analogue carboplatin (CBDCA) and compared the schedule-dependent and pharmacokinetic effects for IL-1 alpha combinations with cDDP and CBDCA. RIF-1 tumor-bearing mice (C3H/HeJ) received i.p. injections of varying doses of CBDCA, alone or concurrently with IL-1 alpha (48 or 480 micrograms/kg). Clonogenic cell kill and tumor regrowth delay were significantly increased when CBDCA was combined with IL-1 alpha, at both doses, compared to either CBDCA or IL-1 alpha alone (P < 0.001 and P < 0.01, respectively). Although pretreatment with IL-1 receptor antagonist blocked the acute tumor hemorrhagic response induced by IL-1 alpha alone, IL-1 receptor antagonist only partially blocked IL-1 alpha enhancement of CBDCA or cDDP-mediated tumor cell kill. The IL-1 alpha enhancement of CBDCA-mediated tumor cell kill was highly schedule dependent, with maximum antitumor activity observed when IL-1 alpha was administered 4-12 h before CBDCA. In contrast, administration of IL-1 alpha from 24 h before or as late as 6 h after cDDP resulted in the same antitumor activity as simultaneous administration of cDDP and IL-1 alpha. Tumor and normal tissue platinum content were significantly increased by IL-1 alpha in animals treated with CBDCA (P < 0.01) but not in those treated with cDDP. The observed differences between cDDP and CBDCA may be explained by their known differential rates of clearance and protein binding affinities and are compatible with an induced alteration in CBDCA pharmacokinetics.
authors.affiliation: Department of Otolaryngology, University of Pittsburgh School of Medicine, Pennsylvania 15213.
authors.forename: M J
authors.initials: MJ
authors.lastname: Chang
authors.forename: W D
authors.initials: WD
authors.lastname: Yu
authors.forename: L M
authors.initials: LM
authors.lastname: Reyno
authors.forename: R A
authors.initials: RA
authors.lastname: Modzelewski
authors.forename: M J
authors.initials: MJ
authors.lastname: Egorin
authors.forename: K
authors.initials: K
authors.lastname: Erkmen
authors.forename: D R
authors.initials: DR
authors.lastname: Vlock
authors.forename: P
authors.initials: P
authors.lastname: Furmanski
authors.forename: C S
authors.initials: CS
authors.lastname: Johnson
mesh_terms: D000818:Animals; D016190:Carboplatin / Q000493:pharmacokinetics / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002945:Cisplatin / Q000493:pharmacokinetics / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D005260:Female; D005354:Fibrosarcoma / Q000737:chemistry / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D007375:Interleukin-1 / Q000494:pharmacology*; D051379:Mice; D008809:Mice, Inbred C3H; D010984:Platinum / Q000032:analysis; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D007375:Interleukin-1; D017472:Receptors, Interleukin-1; D010984:Platinum; D016190:Carboplatin; D002945:Cisplatin